Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

▤ Summary

Nurix Therapeutics released updated Phase 1a/b data for bexobrutideg, its investigational BTK degrader for relapsed/refractory CLL/SLL. The company reported durable responses, including an 83.0% objective response rate in heavily pretreated patients and a 92.9% response rate in a second-line cohort. The update also highlighted encouraging activity in earlier-line patients and a safety profile that remained consistent with prior disclosures. Nurix said the findings support advancing a broader Phase 3 monotherapy program and combination development plans with Roche.

▦ Linked Companies